Yahoo
NasdaqGS - Nasdaq Real Time Price USD

GE HealthCare Technologies Inc. (GEHC)

76.57 +0.15 (+0.20%)
At close: 4:00:01 PM EDT
76.21 -0.36 (-0.47%)
After hours: 4:14:48 PM EDT
Trade GEHC on Coinbase
GEHC Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for GEHC

What's happening with GEHC?

18m ago
Powered by Yahoo Scout

GE HealthCare delivered a stronger-than-expected third quarter, with 6.2% organic revenue growth, margin expansion, and higher 2026 guidance. Pharmaceutical Diagnostics and radiopharmaceuticals remained key growth drivers, while the planned $945 million SOFIE Biosciences acquisitionadds supply-chain opportunity and integration complexity.

Powered by Yahoo Scout
  • Previous Close 76.42
  • Open 77.43
  • Bid 71.53 x 200
  • Ask 82.92 x 200
  • Day's Range 76.20 - 78.21
  • 52 Week Range 58.75 - 89.77
  • Volume 3,967,429
  • Avg. Volume 3,421,165
  • Market Cap (intraday) 34.62B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 16.19
  • EPS (TTM) 4.73
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield 0.16 (0.21%)
  • 1y Target Est 86.80
  • Morningstar Rating Rating available with Stock Picks access

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

www.gehealthcare.com

54,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GEHC
6.46%
S&P 500 (^GSPC)
10.73%

1-Year Return

GEHC
2.30%
S&P 500 (^GSPC)
11.11%

3-Year Return

GEHC
21.86%
S&P 500 (^GSPC)
81.91%

5-Year Return

GEHC
21.54%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 5.51B
Earnings 615M
Profit Margin 11.16%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
8.0%
9.0%
10.0%
11.0%

Analyst Insights

View More

Analyst Price Targets

73.00
86.80 Average
76.57 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/29/2026
Analyst JP Morgan
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 70 -> 80

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.95%

  • Return on Assets (ttm)

    4.99%

  • Return on Equity (ttm)

    20.01%

  • Revenue (ttm)

    21.64B

  • Net Income Avi to Common (ttm)

    2.15B

  • Diluted EPS (ttm)

    4.73

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.83B

  • Total Debt/Equity (mrq)

    87.71%

  • Levered Free Cash Flow (ttm)

    1.83B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: